Cephalon, Inc.

Millennium Pharmaceuticals Limited

Cell Therapeutics, Inc.

Cti Biopharma Corp.

Cell Therapeutics Europe S.r.l.

Nanovector S.r.l.

Alberto Bernareggi

Ernesto Menta

Ambrogio Oliva

Raffaella Bernardini

Paolo G Cassara

Germano D'Arasmo

Sergio De Munari

Sankar Chatterjee

Mohamed A Iqbal

Edmondo Ferretti

Patricia A Messina McLaughlin

Valeria Livi

Gianluca Pardi

Paolo Pavesi

Mario Grugni

Paolo Gasco

Giulio Mariotti

Gabriella Pezzoni

Paolo Nicoli

Maria Rosa Gasco

Germano D'arasmo

Patricia A Messina Mclaughlin

Mohamed Iqbal

Rafaella Bernardini

Sergio De Nunari

Raffaella Bernardnini

The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly of indirectly with proteasome activity.

Proteasome inhibitors and methods of using the same

Injectable pharmaceutical compositions containing 6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione dimaleate as active ingredient in the form of a lyophilized powder with a carrier selected from lactose and dextran, mixed with sodium chloride.

Injectable pharmaceutical compositions of an anthracenedione derivative with anti-tumoral activity

A compound of general formula (I): in which: R is selected from the group consisting of (C-C)alkyl, (C-C)alkenyl, aryl, (C-C)aralkyl; n and m are each independently an integer of two to eight; p is one or two; A is selected from the group consisting of &#x2014;B&#x2014;, &#x2014;B&#x2014;(CH)&#x2014;B&#x2014;, &#x2014;B&#x2014;(CH)&#x2014;B&#x2014;(CH)&#x2014;B&#x2014;, wherein r and z are an integer from 2 to 8, B is a &#x2014;NR&#x2014; or &#x2014;N(R)1/pQgroup, in which R1 is selected from hydrogen, (C-C)alkyl, (C-C)acyl, tert-butoxycarbonyl, and Ris selected from hydrogen and (C-C)alkyl; Qis an anion selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, RCOOwherein Rhas the same meanings as R, independently from one another and R&#x2014;O&#x2014;SOwherein Ris (C-C)alkyl with the proviso that, when Qis selected from chloride, bromide, iodide, nitrate, sulphate, hydrogen sulphate, perchlorate, R is not (C-C)alkyl. 

Bis-platinum complexes with antitumor activity

The present invention provides boronic acid compounds, boronic esters, and compositions thereof that can modulate apoptosis such as by inhibition of proteasome activity. The compounds and compositions can be used in methods of inducing apoptosis and treating diseases such as cancer and other disorders associated directly or indirectly with proteasome activity.

Solid Lipid Nanoparticles of platinum compounds, particularly of antitumor platinum complexes are disclosed. The Nanoparticles of the invention are obtained by a process comprising: a) preparing a first microemulsion by mixing a molten lipid, a surfactant, and optionally a co-surfactant and the platinum compound acqueous solution; b) preparing a solution by mixing a surfactant and optionally a co-surfactant in water, heating to complete solution, preferably at the same melting temperature of the lipid used in a) and adding a co-surfactant; c) dispersing the microemulsion obtained in a) into the solution obtained in b) obtaining a multiple microemulsion c); d) dispersing the microemulsion obtained in c) in aqueous medium at a temperature ranging from 0.5&#xb0; C. to 4&#xb0; C. obtaining a dispersion of solid lipid microspheres; e) washing with aqueous medium through ultrafiltration the obtained lipid microspheres obtained in d) and lyophilizing, optionally in the presence of a bulking agent and of a cryoprotecting agent.

Nanoparticle formulations of platinum compounds

Growing community of inventors

Concorezzo, Italy

Alberto Bernareggi